Radiolabeled oligonucleotides for antisense imaging

Current Organic Synthesis

Volumn 8, Issue 4, 2011, Pages 604-614

  Iyer, Arun K ^a   He, Jiang ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antisense imaging; Antisense therapy; Molecular imaging; Mrna; Pet; Radiopharmaceuticals; Spect

Indexed keywords

EID: 79960006189     PISSN: 15701794     EISSN: None     Source Type: Journal    
DOI: 10.2174/157017911796117241     Document Type: Review

References (137)

1. Nielsen, P., Targeting double stranded DNA with peptide nucleic acid(PNA). Curr. Med. Chem., 2001, 8(5), 545-550.
2. Kuhn, H.; Demidov, V.; Nielsen, P.; Frank-Kamenetskii, M., Anexperimental study of mechanism and specificity of peptide nucleic acid(PNA) binding to duplex DNA. J. Mol. Biol., 1999, 286(5), 1337-1345.
3. Agrawal, S.; Zhao, Q., Antisense therapeutics. Curr. Opin. Chem. Biol.,1998, 2(4), 519-528.
4. Monteith, D.; Levin, A., Synthetic oligonucleotides: the development ofantisense therapeutics. Toxicol. Pathol., 1999, 27(1), 8-13.
5. Gambhir, S., Molecular imaging of cancer with positron emissiontomography. Nat. Rev. Cancer, 2002, 2(9), 683-693.
6. Phelps, M., PET: the merging of biology and imaging into molecular imaging. J. Nucl. Med., 2000, 41(4), 661-681.
7. Wernick, M.; Aarsvold, J., Emission tomography: the fundamentals of PETand SPECT. Academic Press, 2004.
8. Cherry, S., Multimodality Imaging: Beyond PET/CT and SPECT/CT. Semin.Nucl. Med., 2009, 39, 348-353.
9. Dobrucki, L.; Sinusas, A., Molecular imaging: a new approach to nuclear cardiology. Q. J. Nucl. Med. Mol. Imaging, 2005, 49(1), 106-115.
10. Dobrucki, L.; Sinusas, A., Imaging angiogenesis. Curr. Opin. Biotechnol.,2007, 18(1), 90-96.
11. Berger, F.; Gambhir, S., Recent advances in imaging endogenous ortransferred gene expression utilizing radionuclide technologies in livingsubjects: applications to breast cancer. Breast Cancer Res., 2001, 3(1), 28-35.
12. Chatziioannou, A., Instrumentation for molecular imaging in preclinical research: Micro-PET and Micro-SPECT. Proc. Am. Thorac. Soc., 2005, 2,533-536.
13. Hnatowich, D., Antisense and nuclear medicine. J. Nucl. Med., 1999, 40(4),693-703.
14. Hnatowich, D., Antisense imaging: Where are we now? Cancer Biother.Radiopharm., 2000, 15(5), 447-457.
15. Tavitian, B., In vivo antisense imaging. Q. J. Nucl. Med., 2000, 44(3), 236-255.
16. Lewis, M.; Jia, F., Antisense imaging: And miles to go before we sleep? J.Cell. Biochem., 2003, 90(3), 464-472.
17. Dewanjee, M.; Ghafouripour, A.; Werner, R.; Serafini, A.; Sfakianakis, G., Development of sensitive radioiodinated anti-sense oligonucleotide probesby conjugation techniques. Bioconjug. Chem., 1991, 2(4), 195-200.
18. Chesselet, M., In situ hybridization histochemistry. CRC press: 1991.
19. Williams, J.; Mason, P., Hybridization in the analysis of RNA. Nucleic acid hybridization. IRL Press, Oxford, 1985, 152-174.
20. Li, Y. C.; Tan, T. Z.; Zheng, J. G.; Zhang, C., Anti-sense oligonucleotidelabeled with technetium-99m using hydrazinonictinamide derivative and Nhydroxysuccinimidyl S-acetylmercaptoacetyltriglycline: a comparison ofradiochemical behaviors and biological properties. World J. Gastroenterol.,2008, 14(14), 2235-2240.
21. Dolle, F.; Hinnen, F.; Vaufrey, F.; Tavitian, B.; Crouzel, C., A generalmethod for labeling oligodeoxynucleotides with 18 F for in vivo PETimaging. J. Labelled. Comp. Radiopharm., 1997, 39(4), 319-330.
22. Mukherjee, A.; Wickstrom, E.; Thakur, M., Imaging oncogene expression.Eur. J. Radiol., 2009, 70(2), 265-273.
23. Banerjee, S.; Pillai, A.; Raghavan, M.; Ramamoorthy, N., Evolution of Tc-99m in diagnostic radiopharmaceuticals. Semin. Nucl. Med., 2001, 31, 260-277.
24. Tripathi, L.; Kumar, P.; Singh, R., Role of chelates in magnetic resonance imaging studies. J. Cancer Res. Ther., 2009, 5(3), 148-153.
25. Hnatowich, D.; Winnard Jr, P.; Virzi, F.; Fogarasi, M.; Sano, T.; Smith, C.; Cantor, C.; Rusckowski, M.,Technetium-99m labeling of DNA oligonucleotides. J. Nucl. Med., 1995, 36(12), 2306-2314.
26. Mardirossian, G.; Lei, K.; Rusckowski, M.; Chang, F.; Qu, T.; Egholm, M.; Hnatowich, D., In vivo hybridization of technetium-99m-labeled peptidenucleic acid (PNA). J. Nucl. Med., 1997, 38(6), 907-913.
27. Zhang, Y.; Liu, N.; Zhu, Z.; Rusckowski, M.; Hnatowich, D., Influences ofthree chelators (HYNIC, MAG3 and DTPA) on the in vitro and in vivo behaviors of 99m Tc attached to antisense DNA. Eur. J. Nucl. Med., 2000,27, 1700-1707.
28. Hjelstuen, O.; T-nnesen, H.; Bremer, P.; Verbruggen, A., 3 -99mTc-labelingand biodistribution of a CAPL antisense oligodeoxynucleotide. Nucl. Med.Biol., 1998, 25(7), 651-657.
29. Hjelstuen, O.; Saetern, A.; Tonnesen, H.; Bremer, P.; Verbruggen, A., Development of a lyophilized kit formulation for labeling of DNA probeswith 99mTc. Int. J. Pharm., 1999, 190(2), 197-205.
30. Zhang, Y.; He, J.; Liu, G.; Venderheyden, J.; Gupta, S.; Rusckowski, M.; Hnatowich, D., Initial observations of 99mTc labelled locked nucleic acidsfor antisense targeting. Nucl. Med. Commun., 2004, 25(11), 1113-1118.
31. Liu, M.; Wang, R.; Zhang, C.; Yan, P.; Yu, M.; Di, L.; Liu, H.; Guo, F., Noninvasive imaging of human telomerase reverse transcriptase (hTERT)messenger RNA with 99mTc-radiolabeled antisense probes in malignanttumors. J. Nucl. Med., 2007, 48(12), 2028-2036.
32. Liu, G.; Zhang, S.; He, J.; Zhu, Z.; Rusckowski, M.; Hnatowich, D., Improving the Labeling of S-Acetyl NHS- MAG3-Conjugated MorpholinoOligomers. Bioconjug. Chem., 2002, 13(4), 893-897.
33. Liu, G.; Dou, S.; He, J.; Yin, D.; Gupta, S.; Zhang, S.; Wang, Y.; Rusckowski, M.; Hnatowich, D., Replacing 99m Tc with 111 In Improves MORF/cMORF Pretargeting by Reducing Intestinal Accumulation. Appl.Radiat. Isot., 2006, 64, 971-978.
34. Wang, Y.; Liu, G.; Hnatowich, D., Methods for MAG3 conjugation and99mTc radiolabeling of biomolecules. Nat. Protoc., 2006, 1, 1477-1480.
35. Dewanjee, M.; Haider, N.; Narula, J., Imaging with radiolabeled antisenceoligonucleotides for the detection of intracellular messenger RNA andcardiovascular disease. J. Nucl. Cardiol., 1999, 6(3), 345-356.
36. Dewanjee, M.; Ghafouripour, A.; Kapadvanjwala, M.; Dewanjee, S.; Serafini, A.; Lopez, D.; Sfakianakis, G., Noninvasive imaging of c-myconcogene messenger RNA with indium-111-antisense probes in a mammarytumor-bearing mouse model. J. Nucl. Med., 1994, 35(6), 1054-1061.
37. Lewis, M.; Jia, F.; Gallazzi, F.; Wang, Y.; Zhang, J.; Shenoy, N.; Lever, S.; Hannink, M., Radiometal-Labeled Peptide- PNA Conjugates for Targetingbcl-2 Expression: Preparation, Characterization, and in Vitro mRNABinding. Bioconjug. Chem., 2002, 13(6), 1176-1180.
38. Fujibayashi, Y.; Yoshimi, E.; Waki, A.; Sakahara, H.; Saga, T.; Konishi, J.; Yonekura, Y.; Yokoyama, A., A novel 111In-labeled antisense DNA probewith multi-chelating sites (MCS-probe) showing high specific radioactivityand labeling efficiency. Nucl. Med. Biol., 1999, 26(1), 17-21.
39. Mamede, M.; Saga, T.; Ishimori, T.; Higashi, T.; Sato, N.; Kobayashi, H.; Brechbiel, M.; Konishi, J., Hepatocyte targeting of 111In-labeled oligo-DNA with avidin or avidinñdendrimer complex. J. Control. Release, 2004, 95(1),133-141.
40. He, Y.; Panyutin, I.; Karavanov, A.; Demidov, V.; Neumann, R., Sequence specific DNA strand cleavage by 111 In-labeled peptide nucleic acids. Eur.J. Nucl. Med. Mol. Imaging, 2004, 31(6), 837-845.
41. Merkel, O.; Librizzi, D.; Pfestroff, A.; Schurrat, T.; Behe, M.; Kissel, T., In vivo SPECT and real-time gamma camera imaging of biodistribution andpharmacokinetics of siRNA delivery using an optimized radiolabeling andpurification procedure. Bioconjug. chem., 2009, 20, 174-182.
42. Liu, G.; Cheng, D.; Dou, S.; Chen, X.; Liang, M.; Pretorius, P.; Rusckowski, M.; Hnatowich, D., Replacing 99m Tc with 111 In Improves MORF/cMORF Pretargeting by Reducing Intestinal Accumulation. Mol.Imaging Biol., 2009, 11, 303-307.
43. Panyutin, I.; Winters, T.; Feinendegen, L.; Neumann, R., Development ofDNA-based radiopharmaceuticals carrying Auger-electron emitters for antigene radiotherapy. Q. J. Nucl. Med., 2000, 44(3), 256-267.
44. Panyutin, I.; Neumann, R., Sequence-specific DNA double-strand breaks induced by triplex froming 125I labeled oligonucleotides. Nucleic acids res.,1994, 22(23), 4979-4982.
45. Dougan, H.; Hobbs, J.; Weitz, J.; Lyster, D., Synthesis and radioiodination ofa stannyl oligodeoxyribonucleotide. Nucleic acids res., 1997, 25(14), 2897-2901.
46. Kuhnast, B.; Dolle, F.; Terrazzino, S.; Rousseau, B.; Loc'h, C.; Vaufrey, F.; Hinnen, F.; Doignon, I.; Pillon, F.; David, C., General method to labelantisense oligonucleotides with radioactive halogens for pharmacologicaland imaging studies. Bioconjug. Chem., 2000, 11(5), 627-636.
47. Pan, D.; Gambhir, S.; Toyokuni, T.; Iyer, M.; Acharya, N.; Phelps, M.; Barrio, J., Rapid synthesis of a 5 -fluorinated oligodeoxy-nucleotide: Amodel antisense probe for use in imaging with positron emission tomography(PET). Bioorg. Med. Chem. Lett., 1998, 8(11), 1317-1320.
48. Fowler, J.; Wolf, A. Synthesis of carbon-11, fluorine-18, and nitrogen-13labeled radiotracers for biomedical applications. Nuclear Science Series: Nuclear Medicine; NAS-NS-3201, Brookhaven National Lab., Upton, NY(USA),1982.
49. Kuhnast, B.; Dolle, F.; Vaufrey, F.; Hinnen, F.; Crouzel, C.; Tavitian, B., Fluorine-18 labeling of oligonucleotides bearing chemically-modified ribosephosphate backbones. J. Labelled Comp. Radiopharm., 2000, 43(8), 837-848.
50. de Vries, E.; Vroegh, J.; Dijkstra, G.; Moshage, H.; Elsinga, P.; Jansen, P.; Vaalburg, W., Synthesis and evaluation of a fluorine-18 labeled antisenseoligonucleotide as a potential PET tracer for iNOS mRNA expression. Nucl.Med. Biol., 2004, 31(5), 605-612.
51. Hedberg, E.; Langstrom, B., 18 F-Labelling of oligonucleotides usingsuccinimido 4-[18F]-fluorobenzoate. Acta Chem. Scand., 1998, 52(8), 1037-1039.
52. Hedberg, E.; Langstrom, B., Synthesis of 4-([18 F]-Fluoromethyl)phenylisothiocyanate and its use in labelling oligonucleotides. Acta Chem. Scand.,1997, 51(12), 1236-1240.
53. Kuhnast, B.; Dolle, F.; Tavitian, B., Fluorine-18 labeling of peptide nucleicacids. J. Labelled Comp. Radiopharm., 2002, 45(1), 1-11.
54. Kobori, N.; Imahori, Y.; Mineura, K.; Ueda, S.; Fujii, R., Visualization ofmRNA expression in CNS using 11C-labeled phosphorothioateoligodeoxynucleotide. Neuroreport, 1999, 10(14), 2971-2974.
55. Visser, G.; Vos, M.; Davenport, R.; Pike, V.; Medema, J.; Vaalburg, W.,Development of Labelled Antisense Deoxyoligonucleotides (ODNs) for Usein PET. Synthesis of the [11C]-Labelled Dinucleotide [11C]-Thymidylyl (3'-5') Thymidine. J. Labelled Comp. Radiopharm., 1995, 37, 341-343.
56. Mitterhauser, M.; Toegel, S.; Wadsak, W.; Lanzenberger, R.; Mien, L.; Kuntner, C.; Wanek, T.; Eidherr, H.; Ettlinger, D.; Viernstein, H., Pre vivo,ex vivo and in vivo evaluations of [68Ga]-EDTMP. Nucl. Med. Biol., 2007,34(4), 391-397.
57. Maecke, H.; Hofmann, M.; Haberkorn, U., 68Ga-labeled peptides in tumorimaging. J. Nucl. Med. 2005, 46(1), 172S-178S.
58. Roivainen, A.; Tolvanen, T.; Salomaki, S.; Lendvai, G.; Velikyan, I.; Numminen, P.; Valila, M.; Sipila, H.; Bergstrom, M.; Harkonen, P.; Lonnberg, H.; Langstrom, B., 68Ga-labeled oligonucleotides for in vivoimaging with PET. J. Nucl. Med., 2004, 45(2), 347-55.
59. Lendvai, G.; Velikyan, I.; Bergstrom, M.; Estrada, S.; Laryea, D.; Valila, M.; Salomaki, S.; Langstrom, B.; Roivainen, A., Biodistribution of 68Ga-labelledphosphodiester, phosphorothioate, and 2'-O-methyl phosphodiesteroligonucleotides in normal rats. Eur. J. Pharm. Sci., 2005, 26(1), 26-38.
60. Lendvai, G.; Velikyan, I.; Estrada, S.; Eriksson, B.; Lângstr̂m B.; Bergstr̂m, M., Biodistribution of 68Ga-Labeled LNA-DNA Mixmer Antisense Oligonucleotides for Rat Chromogranin-A. Oligonucleotides,2008, 18(1), 33-49.
61. Goodchild, J., Conjugates of oligonucleotides and modified oligonucleotides:a review of their synthesis and properties. Bioconjugate Chem., 1990, 1(3),165-187.
62. Sproat, B. S., Chemical nucleic acid synthesis, modification and labelling.Curr. Opin. Biotechnol., 1993, 4(1), 20-28.
63. Matteucci, M.; Wagner, R., In pursuit of antisense. Nature, 1996, 384,(6604), 20-22.
64. Agarwal, S.; Temsamani, J.; Tang, J., Pharmacokinetics, biodistribution, andstability of oligonucleotide phorphorothidates in mice. Proc. Natl. Acad. Sci.USA, 1991, 88, 7595-7599.
65. Koziolkiewicz, M.; Wojcik, M.; Kobylanska, A.; Karwowski, B.; Rebowska, B.; Guga, P.; Stec, W. J., Stability of stereoregular oligo(nucleosidephosphorothioate)s in human plasma: diastereoselectivity of plasma 3'-exonuclease. Antisense Nucleic Acid Drug Dev., 1997, 7(1), 43-48.
66. Gilar, M.; Belenky, A.; Budman, Y.; Smisek, D. L.; Cohen, A. S., Impact of3'-exonuclease stereoselectivity on the kinetics of phosphorothioateoligonucleotide metabolism. Antisense Nucleic Acid Drug Dev., 1998, 8(1),35-42.
67. Zhou, L.; Morocho, A.; Chen, B.; Cohen, J., Synthesis of phosphorothioatemethylphosphonate oligonucleotide co-polymers. Nucleic acids Res., 1994,22(3), 453-456.
68. Chen, T. L.; Miller, P. S.; Ts'o, P. O.; Colvin, O. M., Disposition andmetabolism of oligodeoxynucleoside methylphosphonate following a singlei.v. injection in mice. Drug. Metab. Dispos., 1990, 18(5), 815-818.
69. Monia, B. P.; Lesnik, E. A.; Gonzalez, C.; Lima, W. F.; McGee, D.; Guinosso, C. J.; Kawasaki, A. M.; Cook, P. D.; Freier, S. M., Evaluation of2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitorsof gene expression. J. Biol. Chem., 1993, 268(19), 14514-14522.
70. Pandolfi, D.; Rauzi, F.; Capobianco, M. L., Evaluation of different types ofend-capping modifications on the stability of oligonucleotides toward 3'- and5'-exonucleases. Nucleosides Nucleotides, 1999, 18(9), 2051-2069.
71. Agrawal, S.; Jiang, Z.; Zhao, Q.; Shaw, D.; Cai, Q.; Roskey, A.; Channavajjala, L.; Saxinger, C.; Zhang, R., Mixed-backboneoligonucleotides as second generation antisense oligonucleotides: in vitroand in vivo studies. Proc. Natl. Acad. Sci. USA, 1997, 94(6), 2620-2625.
72. Hudziak, R. M.; Barofsky, E.; Barofsky, D. F.; Weller, D. L.; Huang, S. B.; Weller, D. D., Resistance of morpholino phosphorodiamidate oligomers toenzymatic degradation. Antisense Nucleic Acid Drug Dev., 1996, 6(4), 267-272.
73. Summerton, J., Weller, D., Morpholino antisense oligomers: design,preparation, and properties. Antisense Nucleic Acid Drug Dev., 1997, 7(3),187-195.
74. Liu, G.; He, J.; Dou, S.; Gupta, S.; Vanderheyden, J.; Rusckowski, M.; Hnatowich, D., Pretargeting in tumored mice with radiolabeled morpholinooligomer showing low kidney uptake. Eur. J. Nucl. Med. Mol. Imaging,2004, 31(3), 417-424.
75. Egholm, M.; Buchardt, O.; Christensen, L.; Behrens, C.; Freier, S.; Driver, D.; Berg, R.; Kim, S.; Norden, B.; Nielsen, P., PNA hybridizes tocomplementary oligonucleotides obeying the WatsonñCrick hydrogenbonding rules. Nature, 1993, 365, 566-568.
76. Good, L.; Nielsen, P. E., Progress in developing PNA as a gene-targeteddrug. Antisense Nucleic Acid Drug Dev., 1997, 7(4), 431-437.
77. Ray, A.; Norden, B., Peptide nucleic acid (PNA): its medical andbiotechnical applications and promise for the future. FASEB J., 2000, 14(9),1041-1060.
78. Grunweller, A.; Hartmann, R., Locked nucleic acid oligonucleotides: thenext generation of antisense agents? BioDrugs, 2007, 21(4), 235-243.
79. Kurreck, J.; Wyszko, E.; Gillen, C.; Erdmann, V., Design of antisenseoligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res., 2002,30(9), 1911-1918.
80. Urbain, J.; Shore, S.; Vekemans, M.; Cosenza, S.; DeRiel, K.; Patel, G.; Charkes, N.; Malmud, L.; Reddy, E., Scintigraphic imaging of oncogeneswith antisense probes: does it make sense? Eur. J. Nucl. Med. Mol. Imaging,1995, 22(6), 499-504.
81. Zhang, Y.; Liu, N.; Zhu, Z.; Rusckowski, M.; Hnatowich, D., Influence ofdifferent chelators (HYNIC, MAG 3 and DTPA) on tumor cell accumulationand mouse biodistribution of technetium-99m labeled to antisense DNA. Eur. J. Nucl. Med. Mol. Imaging, 2000, 27(11), 1700-1707.
82. Zhang, Y.; Wang, Y.; Liu, N.; Zhu, Z.; Rusckowski, M.; Hnatowich, D., Invitro investigations of tumor targeting with 99mTc-labeled antisense DNA. J. Nucl. Med., 2001, 42(11), 1660-1669.
83. Goodchild, J.; Kim, B.; Zamecnik, P. C., The clearance and degradation of oligodeoxynucleotides following intravenous injection into rabbits. Antisense Res. Dev., 1991, 1(2), 153-160.
84. Tidd, D. M.; Warenius, H. M., Partial protection of oncogene, anti-senseoligodeoxynucleotides against serum nuclease degradation using terminalmethylphosphonate groups. Br. J. Cancer, 1989, 60(3), 343-350.
85. Shaw, J. P.; Kent, K.; Bird, J.; Fishback, J.; Froehler, B., Modifieddeoxyoligonucleotides stable to exonuclease degradation in serum. NucleicAcids Res., 1991, 19(4), 747-750.
86. Stein, C. A.; Subasinghe, C.; Shinozuka, K.; Cohen, J. S., Physicochemicalproperties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res.,1988, 16(8), 3209-3221.
87. Maier, M.; Bleicher, K.; Kalthoff, H.; Bayer, E., Enzymatic degradation ofvarious antisense oligonucleotides: monitoring and fragment identificationby MECC and ES-MS. Biomed. Pept. Proteins Nucleic Acids, 1995, 1(4),235-42.
88. Zendegui, J.; Vasquez, K.; Tinsley, J.; Kessler, D.; Hogan, M., In vivostability and kinetics of absorption and disposition of 3'phosphopropyl amineoligonucleotides. Nucleic acids Res., 1992, 20(2), 307-314.
89. Tavitian, B.; Terrazzino, S.; Khnast, B.; Marzabal, S.; Stettler, O.; DollÈ, F.; Deverre, J.; Jobert, A.; Hinnen, F.; Bendriem, B., In vivo imaging ofoligonucleotides with positron emission tomography. Nat. Med., 1998, 4(4),467-471.
90. Hnatowich, D. J., Pharmacokinetic considerations in the development ofoligomers as radiopharmaceuticals. Q. J. Nucl. Med., 1997, 41(2), 91-100.
91. Langstrom, B.; Kihlberg, T.; Bergstrom, M.; Antoni, G.; Bjorkman, M.; Forngren, B.; Forngren, T.; Hartvig, P.; Markides, K.; Yngve, U., Compounds labelled with short-lived beta (+)-emitting radionuclides andsome applications in life sciences. The importance of time as a parameter. Acta Chem. Scand., 1999, 53(9), 651-669.
92. Stein, C., Two problems in antisense biotechnology: in vitro delivery and thedesign of antisense experiments. Biochim. Biophys. Acta., 1999, 1489(1), 45-52.
93. Stein, C., Keeping the biotechnology of antisense in context. Nat.Biotechnol., 1999, 17, 209-209.
94. Srinivasan, S. K.; Tewary, H. K.; Iversen, P. L., Characterization of bindingsites, extent of binding, and drug interactions of oligonucleotides withalbumin. Antisense Res. Dev., 1995, 5(2), 131-139.
95. Benimetskaya, L.; Tonkinson, J. L.; Koziolkiewicz, M.; Karwowski, B.; Guga, P.; Zeltser, R.; Stec, W.; Stein, C. A., Binding of phosphorothioateoligodeoxynucleotides to basic fibroblast growth factor, recombinant solubleCD4, laminin and fibronectin is P-chirality independent. Nucleic Acids Res.,1995, 23(21), 4239-4245.
96. Hawley, P.; Gibson, I., Interaction of oligodeoxynucleotides withmammalian cells. Antisense Nucleic Acid Drug Dev., 1996, 6(3), 185-195.
97. Yakubov, L. A.; Deeva, E. A.; Zarytova, V. F.; Ivanova, E. M.; Ryte, A. S.; Yurchenko, L. V.; Vlassov, V. V., Mechanism of oligonucleotide uptake bycells: involvement of specific receptors? Proc. Natl. Acad. Sci. U S A, 1989,86(17), 6454-6458.
98. Geselowitz, D. A.; Neckers, L. M., Analysis of oligonucleotide binding,internalization, and intracellular trafficking utilizing a novel radiolabeledcrosslinker. Antisense Res. Dev., 1992, 2(1), 17-25.
99. Tavitian, B., In vivo imaging with oligonucleotides for diagnosis and drugdevelopment. Gut, 2003, 52, (Suppl 4), iv40-iv47.
100. Alberts, B.; Bray, D.; Lewis, J.; Raff, M.; Roberts, K.; Watson, J., InMolecular biology of the cell, Garland Pub. New York, 1994, 634-646.
101. Kedzierski, W.; Porter, J., Quantitative study of tyrosine hydroxylase mRNAin catecholaminergic neurons and adrenals during development and aging. Brain Res. Mol. Brain Res., 1990, 7(1), 45-51.
102. Williams, R.; Kass, D.; Kawagoe, Y.; Pak, P.; Tunin, R.; Shah, R.; Hwang,A.; Feldman, A., Endomyocardial gene expression during development ofpacing tachycardia-induced heart failure in the dog. Circ. Res., 1994, 75(4),615-623.
103. Hnatowich, D. J.; Nakamura, K., Antisense targeting in cell culture withradiolabeled DNAs--a brief review of recent progress. Ann. Nucl. Med.,2004, 18(5), 363-368.
104. Nakamura, K.; Fan, C.; Liu, G.; Gupta, S.; He, J.; Dou, S.; Kubo, A.; Rusckowski, M.; Hnatowich, D., Evidence of antisense tumor targeting inmice. Bioconjug. Chem., 2004, 15(6), 1475-1480.
105. Nakamura, K.; Kubo, A.; Hnatowich, D., Antisense targeting of Pglycoproteinexpression in tissue culture. J. Nucl. Med., 2005, 46(3), 509-513.
106. Zhang, Y.; Rusckowski, M.; Liu, N.; Liu, C.; Hnatowich, D., Cationicliposomes enhance cellular/nuclear localization of 99mTc-antisenseoligonucleotides in target tumor cells. Cancer Biother. Radiopharm., 2001,16(5), 411-419.
107. Freier, S., Hybridization: considerations affecting antisense drugs. Antisense Research and Applications. CRC Press, Boca Raton, FL, 1993, 67-82.
108. Younes, C.; Boisgard, R.; Tavitian, B., Labelled oligonucleotides asradiopharmaceuticals: pitfalls, problems and perspectives. Curr. Pharm.Des., 2002, 8(16), 1451-1466.
109. Dokka, S.; Rojanasakul, Y., Novel non-endocytic delivery of antisenseoligonucleotides. Adv. Drug Deliv. Rev., 2000, 44(1), 35-49.
110. Wu-Pong, S.; Weiss, T.; Hunt, C., Antisense c-mycoligodeoxyribonucleotide cellular uptake. Pharm. Res., 1992, 9, 1010-1017.
111. Wu-Pong, S.; Weiss, T.; Hunt, C., Antisense c-myc oligonucleotide cellularuptake and activity. Antisense Res. Dev., 1994, 4(3), 155-163.
112. Stein, C.; Tonkinson, J.; Zhang, L.; Yakubov, L.; Gervasoni, J.; Taub, R.; Rotenberg, S., Dynamics of the internalization of phosphodiesteroligodeoxynucleotides in HL60 cells. Biochemistry, 1993, 32(18), 4855-4861.
113. Pooga, M.; Kut, C.; Kihlmark, M.; Hällbrink, M.; Fernaeus, S.; Raid, R.; Land, T.; Hallberg, E.; Bartfai, T.; Langel, Cellular translocation of proteinsby transportan. FASEB J., 2001, 7801.
114. Gruaz-Guyon, A.; Janevik-Ivanovska, E.; Raguin, O.; De Labriolle-Vaylet, C.; Barbet, J., Radiolabeled bivalent haptens for tumor immunodetection andradioimmunotherapy. Q. J. Nucl. Med., 2001, 45(2), 201-206.
115. Rosi, N.; Giljohann, D.; Thaxton, C.; Lytton-Jean, A.; Han, M.; Mirkin, C., Oligonucleotide-modified gold nanoparticles for intracellular generegulation. Science, 2006, 312(5776), 1027-1030.
116. Patel, P.; Giljohann, D.; Seferos, D.; Mirkin, C., Peptide antisensenanoparticles. Proc. Natl. Acad. Sci. USA, 2008, 105(45), 17222-17226.
117. Thierry, A. R.; Dritschilo, A., Intracellular availability of unmodified,phosphorothioated and liposomally encapsulated oligodeoxynucleotides forantisense activity. Nucleic Acids Res., 1992, 20(21), 5691-5698.
118. Leonetti, J. P.; Degols, G.; Lebleu, B., Biological activity of oligonucleotidepoly(L-lysine) conjugates: mechanism of cell uptake. Bioconjug. Chem.,1990, 1(2), 149-153.
119. Citro, G.; Szczylik, C.; Ginobbi, P.; Zupi, G.; Calabretta, B., Inhibition ofleukaemia cell proliferation by folic acid-polylysine-mediated introduction ofc-myb antisense oligodeoxynucleotides into HL-60 cells. Br. J. Cancer,1994, 69(3), 463-467.
120. Kim, S.; Mok, H.; Jeong, J.; Kim, S.; Park, T., Comparative Evaluation ofTarget-Specific GFP Gene Silencing Efficiencies for Antisense ODN,Synthetic siRNA, and siRNA Plasmid Complexed with PEI- PEG- FOLConjugate. Bioconjug. Chem., 2006, 17(1), 241-244.
121. Jeong, J.; Kim, S.; Park, T., A new antisense oligonucleotide delivery systembased on self-assembled ODNñPEG hybrid conjugate micelles. J. Control.Release, 2003, 93(2), 183-191.
122. Hollins, A.; Benboubetra, M.; Omidi, Y.; Zinselmeyer, B.; Schatzlein, A.; Uchegbu, I.; Akhtar, S., Evaluation of generation 2 and 3 poly(propylenimine) dendrimers for the potential cellular delivery of antisenseoligonucleotides targeting the epidermal growth factor receptor. Pharm. Res.,2004, 21(3), 458-466.
123. Choi, J.; Lee, E.; Choi, Y.; Jeong, Y.; Park, J., Poly (ethylene glycol)-blockpoly(L-lysine) dendrimer: novel linear polymer/dendrimer block copolymerforming a spherical water-soluble polyionic complex with DNA. Bioconjug.Chem., 1999, 10(1), 62-65.
124. Ropert, C.; Malvy, C.; Couvreur, P., Inhibition of the Friend retrovirus byantisense oligonucleotides encapsulated in liposomes: mechanism of action.Pharm. Res., 1993, 10(10), 1427-33.
125. Wang, S.; Lee, R. J.; Cauchon, G.; Gorenstein, D. G.; Low, P. S., Delivery ofantisense oligodeoxyribonucleotides against the human epidermal growthfactor receptor into cultured KB cells with liposomes conjugated to folate viapolyethylene glycol. Proc. Natl. Acad. Sci. U S A, 1995, 92(8), 3318-3322.
126. Noguchi, A.; Furuno, T.; Kawaura, C.; Nakanishi, M., Membrane fusionplays an important role in gene transfection mediated by cationic liposomes. FEBS Lett., 1998, 433(1-2), 169-173.
127. Manoharan, M., Oligonucleotide conjugates as potential antisense drugs withimproved uptake, biodistribution, targeted delivery, and mechanism ofaction. Antisense Nucleic Acid Drug Dev., 2002, 12(2), 103-128.
128. Pastorino, F.; Marimpietri, D.; Brignole, C.; Paolo, D.; Pagnan, G.; Daga, A.; Piccardi, F.; Cilli, M.; Allen, T.; Ponzoni, M.,Ligand-targeted liposomaltherapies of neuroblastoma. Curr. Med. Chem., 2007, 14(29), 3070-3078.
129. Iyer, A.; Khaled, G.; Fang, J.; Maeda, H., Exploiting the enhancedpermeability and retention effect for tumor targeting. Drug Discov. Today,2006, 11(17-18), 812-818.
130. Juliano, R.; Akhtar, S., Liposomes as a drug delivery system for antisenseoligonucleotides. Antisense Res. Dev., 1992, 2(2), 165-176.
131. Pakunlu, R.; Wang, Y.; Saad, M.; Khandare, J.; Starovoytov, V.; Minko, T., In vitro and in vivo intracellular liposomal delivery of antisenseoligonucleotides and anticancer drug. J. Control. Release, 2006, 114(2), 153-162.
132. Zelphati, O.; Szoka, F., Liposomes as a carrier for intracellular delivery ofantisense oligonucleotides: a real or magic bullet? J. Control. Release, 1996,41(1-2), 99-119.
133. Conrad, A. H.; Behlke, M. A.; Jaffredo, T.; Conrad, G. W., Optimallipofection reagent varies with the molecular modifications of the DNA. Antisense Nucleic Acid Drug Dev., 1998, 8(5), 427-34.
134. Nestle, F. O.; Mitra, R. S.; Bennett, C. F.; Chan, H.; Nickoloff, B. J.,Cationic lipid is not required for uptake and selective inhibitory activity ofICAM-1 phosphorothioate antisense oligonucleotides in keratinocytes. J.Invest. Dermatol., 1994, 103(4), 569-575.
135. Maus, U.; Rosseau, S.; Mandrakas, N.; Schlingensiepen, R.; Maus, R.; Muth, H.; Grimminger, F.; Seeger, W.; Lohmeyer, J., Cationic lipids employed forantisense oligodeoxynucleotide transport may inhibit vascular cell adhesionmolecule-1 expression in human endothelial cells: a word of caution. Antisense Nucleic Acid Drug Dev., 1999, 9(1), 71-80.
136. Filion, M.; Phillips, N., Toxicity and immunomodulatory activity ofliposomal vectors formulated with cationic lipids toward immune effectorcells. Biochim. Biophys. Acta., 1997, 1329(2), 345-356.
137. Tavitian, B.; Marzabal, S.; Boutet, V.; Ķhnast, B.; Terrazzino, S.; Moynier, M.; DollÈ, F.; Deverre, J.; Thierry, A., Characterization of syntheticanionic vector for oligonucleotide delivery using in vivo whole bodydynamic imaging. Pharm. Res., 2002, 19(4), 367-376.